Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma

References

• Global Initiative for Asthma GINA. 2020 [cited 2021 Oct 10]. Available from: https://ginasthma.org/
   Google Scholar
• Agache I, Akdis C, Jutel M, et al. Untangling asthma phenotypes and endotypes. Allergy. 2012 Jul;67(7):835–846.
   PubMed Web of Science ®Google Scholar
• Chung KF, Adcock IM. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy. 2019 Sep;74(9):1649–1659.
   PubMed Web of Science ®Google Scholar
• Hekking PP, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015 Apr;135(4):896–902.
   PubMed Web of Science ®Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343–373.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J. 2012 Oct;6(4):215–227.
   PubMed Web of Science ®Google Scholar
• Stanford RH, Gilsenan AW, Ziemiecki R, et al. Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J Asthma. 2010 Apr;47(3):257–262.
   PubMed Web of Science ®Google Scholar
• Yaghoubi M, Adibi A, Safari A, et al. The projected economic and health burden of uncontrolled asthma in the United States. Am J Respir Crit Care Med. 2019 Nov 1;200(9):1102–1112.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004 Oct 15;170(8):836–844.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012 Sep 27;367(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016 Jan;21(1):CD011721.
   Google Scholar
• Kerstjens HA, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015 May;3(5):367–376.
   PubMed Web of Science ®Google Scholar
• Paggiaro P, Halpin DM, Buhl R, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):104–13 e2.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019 Nov9;394(10210):1737–1749.
   PubMed Web of Science ®Google Scholar
• Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2020 Sep 9; 9(1):69-84.
   Google Scholar
• Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170:106021.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020 Oct;8(10):1000–1012.
   PubMed Web of Science ®Google Scholar
• Canonica GW. Treating asthma as an inflammatory disease. Chest. 2006 Jul;130(1Suppl):21S–28S.
   PubMedGoogle Scholar
• Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019 Jul;144(1):1–12.
   PubMed Web of Science ®Google Scholar
• Horvath G, Wanner A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J. 2006 Jan;27(1):172–187.
   PubMed Web of Science ®Google Scholar
• Hubner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005 Aug;25(3):469–488.
   PubMed Web of Science ®Google Scholar
• Cowie RL, Giembycz MA, Leigh R. Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children. Expert Opin Pharmacother. 2009 Aug;10(12):2009–2014.
   PubMed Web of Science ®Google Scholar
• Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019 Jun;53(6):1901046.
   PubMed Web of Science ®Google Scholar
• Spada F, Barnes TM, Greive KA. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids. Australas J Dermatol. 2018 Aug;59(3):e168–e174.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Derom E, Kanniess F, et al. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J. 2007 May;29(5):871–878.
   PubMed Web of Science ®Google Scholar
• Sturton RG, Trifilieff A, Nicholson AG, et al. Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther. 2008 Jan;324(1):270–275.
   PubMed Web of Science ®Google Scholar
• Chuchalin AG, Tsoi AN, Richter K, et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med. 2007 Oct;101(10):2065–2075.
   PubMed Web of Science ®Google Scholar
• Beasley RW, Donohue JF, Mehta R, et al. Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial. BMJ Open. 2015 Feb 3;5(2):e006131.
   PubMed Web of Science ®Google Scholar
• Murphy L, Rennard S, Donohue J, et al. Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD. Drugs. 2014 Sep;74(14):1635–1657.
   PubMed Web of Science ®Google Scholar
• Miller D, Vaidya S, Jauernig J, et al. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients. Respir Res. 2020 Sep 23;21(1):248.
   PubMed Web of Science ®Google Scholar
• Kudlak M, Tadi P Physiology, muscarinic receptor. StatPearls. Treasure Island (FL); 2021.
   Google Scholar
• Moss R, Sachse FB, Moreno-Galindo EG, et al. Modeling effects of voltage dependent properties of the cardiac muscarinic receptor on human sinus node function. PLoS Comput Biol. 2018 Oct;14(10):e1006438.
   PubMed Web of Science ®Google Scholar
• Price D, Fromer L, Kaplan A, et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim Care Respir Med. 2014 Jul 17;24(1):14023.
   PubMedGoogle Scholar
• Gosens R, Gross N. The mode of action of anticholinergics in asthma. Eur Respir J. 2018 Oct;52(4):1701247.
   PubMed Web of Science ®Google Scholar
• Gwilt CR, Donnelly LE, Rogers DF. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol Ther. 2007 Aug;115(2):208–222.
   PubMed Web of Science ®Google Scholar
• Haddad EB, Patel H, Keeling JE, et al. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and Guinea-pig airways. Br J Pharmacol. 1999 May;127(2):413–420.
   PubMed Web of Science ®Google Scholar
• Sykes DA, Dowling MR, Leighton-Davies J, et al. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther. 2012 Nov;343(2):520–528.
   PubMed Web of Science ®Google Scholar
• Fukunaga K, Kume H, Oguma T, et al. Involvement of Ca(2+) signaling in the synergistic effects between muscarinic receptor antagonists and beta(2)-adrenoceptor agonists in airway smooth muscle. Int J Mol Sci. 2016 Sep 21;17(9):1590.
   Web of Science ®Google Scholar
• Hansel TT, Neighbour H, Erin EM, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest. 2005 Oct;128(4):1974–1979.
   PubMed Web of Science ®Google Scholar
• Talwar D, Bendre S. Health-related effects of home nebulization with glycopyrronium on difficult-to-treat asthma: post-hoc analyses of an observational study. Interact J Med Res. 2020 Apr 29;9(2):e17863.
   PubMed Web of Science ®Google Scholar
• Blais CM, Davis BE, Cockcroft DW. Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics. Respir Med. 2016 Sep;118:96–101.
   PubMed Web of Science ®Google Scholar
• Blais CM, Davis BE, Cockcroft DW. The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Respir Res. 2017 Aug 2;18(1):146.
   PubMed Web of Science ®Google Scholar
• Matera MG, Belardo C, Rinaldi M, et al. Emerging muscarinic receptor antagonists for the treatment of asthma. Expert Opin Emerg Drugs. 2020 Jun;25(2):123–130.
   PubMed Web of Science ®Google Scholar
• Kerwin E, Wachtel A, Sher L, et al. Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: a randomized controlled trial. Respir Med. 2018 Jun;139:39–47.
   PubMed Web of Science ®Google Scholar
• Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs. 2001;61(9):1325–1350.
   PubMed Web of Science ®Google Scholar
• Valotis A, Neukam K, Elert O, et al. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci. 2004 May;93(5):1337–1350.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Cuda G, et al. Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci. 2003 Feb 21;72(14):1549–1561.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol. 2006 Mar 8;533(1–3):2–14.
   PubMed Web of Science ®Google Scholar
• Clark AR. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? J Endocrinol. 2003 Jul;178(1):5–12.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Crimi C, et al. Clinical relevance of understanding mitogen-activated protein kinases involved in asthma. Expert Rev Respir Med. 2020 May;14(5):501–510.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Vatrella A, Busceti MT, et al. Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma. Pulm Pharmacol Ther. 2016 Oct;40:15–21.
   PubMed Web of Science ®Google Scholar
• Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol. 1995 Jan;268(1 Pt 1):L41–6.
   PubMed Web of Science ®Google Scholar
• Scott MG, Swan C, Wheatley AP, et al. Identification of novel polymorphisms within the promoter region of the human beta2 adrenergic receptor gene. Br J Pharmacol. 1999 Feb;126(4):841–844.
   PubMed Web of Science ®Google Scholar
• Profita M, Gagliardo R, Di Giorgi R, et al. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy. 2005 Mar;60(3):323–329.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Muzzio CC, Vatrella A, et al. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting beta2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment. Expert Opin Pharmacother. 2015;16(13):2009–2021.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Biochemical basis of asthma therapy. J Biol Chem. 2011 Sep 23;286(38):32899–32905.
   PubMed Web of Science ®Google Scholar
• Mak JC, Hisada T, Salmon M, et al. Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. Br J Pharmacol. 2002 Feb;135(4):987–996.
   PubMed Web of Science ®Google Scholar
• Vatrella A, Maglio A, Pelaia C, et al. Pharmacotherapeutic strategies for critical asthma syndrome: a look at the state of the art. Expert Opin Pharmacother. 2020 Aug;21(12):1505–1515.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Proietto A, Matera MG. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc). 2010 Mar;46(3):139–150.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Maselli R, Matera MG. Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium. Pharmacology. 2014;94(5–6):249–258.
   PubMed Web of Science ®Google Scholar
• Lombardi D, Cuenoud B, Kramer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci. 2009 Dec 8;38(5):533–547.
   PubMed Web of Science ®Google Scholar
• Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem. 1999 Jan 8;274(2):1005–1010.
   PubMed Web of Science ®Google Scholar
• Holden NS, Bell MJ, Rider CF, et al. beta2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19713–19718.
   PubMed Web of Science ®Google Scholar
• Hall IP. Second messengers, ion channels and pharmacology of airway smooth muscle. Eur Respir J. 2000 Jun;15(6):1120–1127.
   PubMed Web of Science ®Google Scholar
• Pelaia G, Marsico SA. Regulation of beta 2-adrenergic receptors and the implications for bronchial asthma: an update. Monaldi Arch Chest Dis. 1994 Apr;49(2):125–130.
   PubMedGoogle Scholar
• Cazzola M, Calzetta L, Segreti A, et al. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. COPD. 2015 Apr;12(2):175–181.
   PubMedGoogle Scholar
• Buhl R, Nikolaev I, Tillmann HC, et al. Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma. Pulm Pharmacol Ther. 2021 Jul 28;70:102068.
   PubMed Web of Science ®Google Scholar
• Vaidya S, Jauernig J, Ethell B, et al. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. Pulm Pharmacol Ther. 2020 Oct;64:101964.
   PubMed Web of Science ®Google Scholar
• Kornmann O, Mucsi J, Kolosa N, et al. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: phase III randomised QUARTZ study findings. Respir Med. 2020 Jan;161:105809.
   PubMed Web of Science ®Google Scholar
• van Zyl-smit RN, Krull M, Gessner C, et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. Lancet Respir Med. 2020 Oct;8(10):987–999.
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri L, Lahousse L, et al. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Allergy. 2021 Sep 3.
   Google Scholar
• Kim LHY, Saleh C, Whalen-Browne A, et al. Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 22;325(24):2466–2479.
   PubMed Web of Science ®Google Scholar
• Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017 Feb;49(2).
   Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001 Aug;23(8):1296–310.
   PubMed Web of Science ®Google Scholar
• Lindsay JT, Heaney LG. Nonadherence in difficult asthma - facts, myths, and a time to act. Patient Prefer Adherence. 2013;7:329–36.
   PubMed Web of Science ®Google Scholar
• Elliott RA. Poor adherence to anti-inflammatory medication in asthma. Dis Manag Health Out. 2006;14(4):223–233.
   Google Scholar
• Azzi E, Srour P, Armour C, et al. Practice makes perfect: self-reported adherence a positive marker of inhaler technique maintenance. NPJ Prim Care Respir Med. 2017 Apr 24;27(1):29.
   PubMedGoogle Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4;353(5):487–97.
   PubMed Web of Science ®Google Scholar
• Van Sickle D, Barrett MA, Humblet O, et al. Randomized, controlled study of the impact of a mobile health tool on asthma SABA use, control and adherence. European Respiratory Journal 2016;48:PA1018.
   Google Scholar
• Mosnaim GS, Stempel DA, Gonzalez C, et al. The Impact of Patient Self-Monitoring Via Electronic Medication Monitor and Mobile App Plus Remote Clinician Feedback on Adherence to Inhaled Corticosteroids: A Randomized Controlled Trial. J Allergy Clin Immunol Pract. 2021 Apr;9(4):1586–1594.
   PubMed Web of Science ®Google Scholar
• Delea TE, Stanford RH, Hagiwara M, et al. Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs*. Curr Med Res Opin. 2008 Dec;24(12):3435–42.
   PubMed Web of Science ®Google Scholar
• Barrett M, Combs V, Su JG, et al. AIR Louisville: Addressing Asthma With Technology, Crowdsourcing, Cross-Sector Collaboration, And Policy. Health Aff (Millwood). 2018 Apr;37(4):525–534.
   PubMed Web of Science ®Google Scholar
• Merchant RK, Inamdar R, Quade RC. Effectiveness of Population Health Management Using the Propeller Health Asthma Platform: A Randomized Clinical Trial. J Allergy Clin Immunol Pract. 2016 May-Jun;4(3):455–63.
   PubMed Web of Science ®Google Scholar
• Merchant RK, Szefler SJ, Bender BG, et al. Impact of a digital health intervention on asthma resource utilization. World Allergy Organ J. 2018;11(1):28.
   PubMedGoogle Scholar
• Merchant R, Inamdar R, Henderson K, et al. Digital health intervention for asthma: patient-reported value and usability. JMIR Mhealth Uhealth. 2018 Jun 4;6(6):e133.
   PubMed Web of Science ®Google Scholar
• Eurpean Medicines Agency E. Human medicines: highlights of 2020; 2020 [cited 2021 Oct 10]. Available from: https://www.ema.europa.eu/en/news/human-medicines-highlights-2020
   Google Scholar